Hans-Ulrich Demuth
Keine laufenden Positionen mehr
Karriereverlauf von Hans-Ulrich Demuth
Ehemalige bekannte Positionen von Hans-Ulrich Demuth
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.1997 | 31.01.2013 |
| Gründer | 25.07.1997 | 31.01.2013 | |
| Hochschule Anhalt | Corporate Officer/Principal | - | - |
Ingenium Pharmaceuticals GmbH
 Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Vorstandsvorsitzender | 04.11.2009 | - |
| Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - | - |
Ausbildung von Hans-Ulrich Demuth
| Martin-Luther-Universität Halle-Wittenberg | Undergraduate Degree |
Statistik
International
| Deutschland | 4 |
| 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Ingenium Pharmaceuticals GmbH
Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Commercial Services |
- Börse
- Insiders
- Hans-Ulrich Demuth
- Erfahrung
